Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03495869
Other study ID # HM20012559
Secondary ID U54DA038999
Status Completed
Phase
First received
Last updated
Start date June 21, 2018
Est. completion date March 16, 2020

Study information

Verified date July 2021
Source Virginia Commonwealth University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The overall goal of this project is to collect preliminary data on psychosocial measures and behavioral performance comparing individuals with Opioid Use Disorder, Cocaine Use Disorder, dual diagnosis of Opioid and Cocaine Use Disorder, and Healthy Controls in an effort to determine overall feasibility of a phenotypic "fingerprint" for cohorts of individuals with addictions for use during clinical trials.


Description:

There is profound heterogeneity of subjects in clinical studies of addictions, with patients being diagnosed by the primary substance of use. As a result, utilizing current DSM addictions classification leads to problems with signal detection and hamper the progress of the development of new drugs and treatments for substance use disorders (SUDs). Getting beyond the DSM-5 based definitions is necessary to "fingerprint" addiction phenotypes and endophenotypes, using machine-learning analyses of big data. A detailed in-depth assessment of addiction phenotypes (deep phenotyping) may also include neuroimaging. In an effort to develop a "fingerprint" for addiction phenotypes, NIDA established a Workgroup to develop a phenotyping battery of tests and self-rated psychometric scales, supplemented by resting state fMRI to be administered to participants in any extramural clinical trial where addictions are assessed. The final phenotyping battery content was determined via consensus from both the selected experts- consultants group and the NIDA workgroup, and as such, the battery requires feasibility and validation study to finalize its content. The NIDA Phenotyping Assessment Battery (PhAB) covers six neurofunctional addiction domains: Metacognition, Interoception, Cognition/Executive Function, Reward/Incentive Salience, Emotion/Negative Emotionality, and Sleep/Circadian Rhythm. The PhAB is meant to be administered during a Phenotyping visit - an extension of a screening visit in any clinical trial addictions protocol. In addition to the PhAB, the group also developed an ancillary set of measures to be administered in conjunction with the PhAB in any addictions clinical trial during the Phenotyping visit. The Platform Instruments include structured interviews, diagnostic measures (e.g., MINI), self report scales of symptom severity (e.g., ASRS-ADHD, VAS-Pain), trauma history (CTQ), computer-administered measures of intelligence (e.g., Shipley), and substance use measures (FTND, Timeline Follow-back), etc. Clinical trial investigators would administer these scales and behavioral tasks in addition to protocol nonspecific assessments (e.g., demographics) and medical evaluations (e.g, medical history and physical exams, genotyping, and labs) which could be done at Screening. This study is a feasibility, construct and face validity study. The primary outcome measure is time taken to complete the battery, and rates of successful study completion


Recruitment information / eligibility

Status Completed
Enrollment 368
Est. completion date March 16, 2020
Est. primary completion date March 16, 2020
Accepts healthy volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria (Individuals with SUDs) - Males and females between 18 and 70 years-of-age. - Current DSM-5 primary Substance Use Disorder: Opioid, marijuana, stimulants (individuals with multiple types of substance use (e.g., opioid/marijuana will be included) - Have no contraindications for study participation as determined by medical history and concomitant medications. - Be able to demonstrate an understanding of study procedures and follow instructions including behavioral laboratory testing. - Be able and willing to comply with scheduled visits, and other study procedures. - Be able to read and complete forms and interviews in English. Inclusion Criteria (Non-drug Using Healthy Controls) - Males and females between 18 and 70 years of age. - Have no contraindications for study participation as determined by medical history and concomitant medications. - Be able to demonstrate an understanding of study procedures and follow instructions including behavioral laboratory testing. - Be able and willing to comply with scheduled visits, and other study - Be able to read and complete forms and interviews in English. General Exclusion Criteria - Current psychosis, mania, or suicidal/homicidal ideation - Meet current DSM-5 diagnosis of any psychoactive substance use disorder other than opioids,marijuana, stimulants, or nicotine. Diagnosis of mild to moderate use disorder for alcohol will not be considered exclusionary for any SUD group. - Have a history of seizures (excluding childhood febrile seizures), or loss of consciousness from traumatic injury for more than 30 minutes. - Have any other illness, or condition, which in the opinion of the PI or study physician would preclude safe and/or successful completion of the study. MRI Exclusion Criteria - Metal fragments or implants, and/or history of fear of being in closed spaces for MRI scans. - Currently pregnant or nursing.

Study Design


Locations

Country Name City State
United States VCU Institute for Drug and Alcohol Studies Richmond Virginia

Sponsors (2)

Lead Sponsor Collaborator
Virginia Commonwealth University National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Performance on Measures of Cognition Across Conditions Performance (time to complete)
#correct) on behavioral tasks which examine cognitive functioning (e.g., Backwards digit span, and stop signal reaction task)
5 hours
Other Performance on Measures of Reward Processing Across Conditions Performance (time to complete)
#correct) on behavioral tasks which examine Reward processing (e.g., hypothetical purchase task) and subscale and total scale scores on self-report measures of reward processing (SUPP-S)
5 hours
Other Performance on Measures of Negative Emotionality Across Conditions Performance (time to complete)
#correct) on behavioral tasks which examine Negative Emotionality (Emotional go/nogo) and subscale and total scale scores on self-report measures of Negative Emotionality (Buss Perry Aggression)
5 hours
Other Self-report on Measure of Interoception Across Conditions Performance (time to complete) 5 hours
Other Self-report on Measure of Metacognition Across Conditions Performance (time to complete) 5 hours
Other Self-report on Measure of Sleep Quality Across Conditions Performance (time to complete) 5 hours
Other Between-group Differences in Brain Connectivity as Measured by Spectral Dynamic Causal Modeling (DCM) and Deterministic Dynamic Causal Modeling Between-group differences in brain connectivity as measured by Spectral dynamic causal modeling (DCM) and Deterministic dynamic causal modeling 1 month
Primary Retention Number of dropouts 1 month
Secondary Time to Complete Battery Time to complete the assessment batteries will also be recorded for each task and each participant. 5 hours
Secondary Non-completers of the Battery and Platform Instruments Number of study completers who did not complete the full battery and platform instruments 5 hours
See also
  Status Clinical Trial Phase
Recruiting NCT04157062 - An Open-Label Trial of Repetitive Transcranial Magnetic Stimulation for Opioid Use Disorder N/A
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Completed NCT04505540 - Start Treatment and Recovery for Opioid Use Disorder N/A
Completed NCT03065049 - Transforming Recovery Through Exercise and Community N/A
Completed NCT04080037 - Assessing Opioid Care Practices Using CPV Patient Simulation Modules N/A
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Suspended NCT05001789 - Cognitive Functioning in Opioid Use Disorder N/A
Recruiting NCT04650386 - Examining an Adaptive Approach to Providing Psychosocial Support to Buprenorphine Patients N/A
Completed NCT03715634 - Study of a Novel Subcutaneous Depot Formulation of Buprenorphine Phase 1
Enrolling by invitation NCT04991974 - Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine Phase 2/Phase 3
Completed NCT04122755 - Single Ascending Dose Study of ALA-1000 Phase 1
Recruiting NCT05049460 - Adjunctive Transcranial Stimulation to Reduce Impulsivity in Opiate Use Disorder N/A
Recruiting NCT05028998 - COVID-19-Related Opioid Treatment Policy Evaluation
Recruiting NCT04927143 - Encouraging Abstinence Behavior in a Drug Epidemic Phase 2
Completed NCT05047627 - Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder N/A
Active, not recruiting NCT04129580 - reSET-O RCT (Randomized Controlled Trial) N/A
Recruiting NCT03923374 - Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
Suspended NCT02687360 - Imaging the Effects of rTMS on Chronic Pain N/A
Completed NCT04056182 - Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment Phase 2
Completed NCT03766893 - Medication Maintenance Therapy in Community Pharmacy Settings Early Phase 1